生物标志物和阿尔茨海默氏病:一个参考文献分析
Linyi Yang1, Jingyan Zeng2, Linlin Li1
1Department of Neurology, Suining Central Hospital, Suining, China.
Frontiers in aging neuroscience
|November 14, 2024
概括
这种对阿尔茨海默病生物标志物的图书统计分析显示,研究势头略有下降,但质量并没有下降. 加强国际合作对于未来阿尔茨海默病生物标志物研究的进展至关重要.
科学领域:
- 神经科学是一个神经科学.
- 生物标志物 生物标志物
- 阿尔茨海默氏症疾病研究研究
背景情况:
- 阿尔茨海默病 (AD) 诊断和治疗生物标志物是重要的研究重点.
- 了解AD生物标志物研究的前景对于未来的进展至关重要.
研究的目的:
- 进行对阿尔茨海默病生物标志物研究的文献分析.
- 增强对AD生物标志物研究当前状态和趋势的理解.
主要方法:
- 从科学引文索引 (科学网) 获取文献的图书统计分析.
- 从2006年1月1日至2022年11月14日收集的数据.
- 使用CiteSpace软件进行的可视化和分析.
主要成果:
- 总共有1138篇论文被分析.
- 美国在出版物 (607篇论文) 中领先,中国排名第六 (84篇论文).
- 确定了关键的研究人员和高度引用的文章/期刊,包括Blennow Kaj,Zetterberg Henrik,Morris John C,Trojanowski John Q和NEUROLOGY期刊.
结论:
- 全球对AD生物标志物的研究势头略有下降,但研究质量仍然很高.
- 建议各国,机构和研究人员加强国际合作.
- 未来的努力应优先考虑促进国际伙伴关系,以推进AD生物标志物研究.
相关概念视频
01:26Alzheimer's Disease: Overview
448
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
448
01:22Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165